Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dabocemagene autoficel - Fibrocell Science

Next Previous
Search
Drug Profile

Dabocemagene autoficel - Fibrocell Science

Alternative Names: D-Fi; FCX-007; Fibroblast epidermolysis bullosa cell therapy -Fibrocell/Intrexon; Fibroblast epidermolysis bullosa dystrophica cell therapy - Fibrocell/Intrexon; Fibroblast epidermolysis bullosa dystrophica gene thearpy - Fibrocell/Intrexon; Fibroblast epidermolysis bullosa gene therapy -Fibrocell/Intrexon; Fibroblast-RDEB-cell-therapy-Fibrocell/Intrexon; Fibroblast-RDEB-gene-therapy-Fibrocell/Intrexon; Genetically modified human dermal fibroblast-collagen VII; Genetically-Modified Autologous Human Dermal Fibroblasts; GM-HDF-COL7

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fibrocell Science
  • Developer Castle Creek Pharmaceuticals; Fibrocell Science; Precigen Inc
  • Class Cell therapies; Fibroblast cell therapies; Gene therapies; Skin disorder therapies
  • Mechanism of Action Cell replacements; Collagen type VII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Epidermolysis bullosa dystrophica

Most Recent Events

  • 28 Mar 2025 Phase-III clinical trials in Epidermolysis bullosa dystrophica (In children, In adults, In adolescents, In the elderly) in USA (Intradermal) (NCT06892639)
  • 10 Mar 2025 Debcoemagene autoficel receives Rare Pediatric Disease designation for Epidermolysis bullosa dystrophica in USA, prior to March 2025
  • 07 Dec 2022 Dabocemagene autoficel is still in phase III trials for Epidermolysis bullosa in USA (NCT04213261)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top